New hope for the development of Alzheimer's disease therapeutics from Qiagen!

New hope for the development of Alzheimer's disease therapeutics from Qiagen!

Molecular Diagnostics

August 30, 2018

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by two types of lesions in the brain: extracellular senile plaques consisting of APP-derived amyloid ß (Aß) peptide and intracellular neurofibrillary tangles build out of hyperphosphorylated microtubule-associated tau protein. 

One process that could contribute to memory loss in AD due to synapse loss and neuronal cell death is the intracellular caspase cleavage of the amyloid precursor protein (APP), producing APP delta C31 and C31.

This review focuses on a high-throughput screening of small molecules that inhibit the APP-C31 generating cleavage pathway as part of AD drug discovery.

Read the full story!

New TP53 MASTR

New TP53 MASTR

Molecular Diagnostics

Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay for the identification of mutations in the entire coding region of TP53.




September 29, 2015 More +
Protease and phosphatase inhibitor cocktails

Protease and phosphatase inhibitor cocktails

Molecular Diagnostics

Protease and phosphatase inhibitors are essential components of most cell lysis and protein isolation procedures. Abcam has developed a range of convenient and easy to use protease and phosphatase inhibitor cocktails, which are suitable for a variety of applications.

April 30, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us